Hyperpolarized metabolic MRI is revolutionizing how we monitor treatment effect in cancer and cardiac diseases. This novel molecular imaging technique can detect treatment effect much earlier than the conventional imaging and Positron Emission Tomography. Our next-generation hyperpolarizer is the first in the USA. We have active research projects in gastric cancer, brain tumor, new contrast agent development, and more.
Vascular dysfunction is increasingly recognized as a key contributor to the development of Alzheimer’s disease (AD) and alterations in brain perfusion are known to be present long before the clinical symptoms of AD develop, perhaps even preceding amyloid-beta plaque accumulation, tau protein deposition, and brain atrophy. We are investigating the most promising, noninvasive cerebrovascular imaging biomarkers that are sensitive and specific to the cerebrovascular alterations that occur in AD in its early stages.
